Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria

Area of Science:

• Hematology
• Immunology
• Pharmacology

Background:

• Eculizumab has transformed paroxysmal nocturnal hemoglobinuria (PNH) treatment by inhibiting the complement system.
• Despite eculizumab's success, unmet clinical needs persist, driving the development of novel complement inhibitors.

Purpose of the Study:

• To review emerging complement inhibitors for PNH management.
• To discuss novel strategies targeting C5 and C3 complement components.
• To anticipate the clinical impact of these new agents based on PNH biology.

Main Methods:

• Review of novel anti-C5 agents (monoclonal antibodies, small molecules, siRNA) and upstream inhibitors (anti-C3, factor D/B inhibitors).
• Analysis of preliminary clinical data and PNH pathophysiology.
• Comparison of potential benefits regarding efficacy, safety, and patient convenience.

Main Results:

• Novel anti-C5 agents aim for improved convenience (longer dosing, subcutaneous administration) while maintaining eculizumab's efficacy and safety.
• Upstream inhibitors targeting C3 may offer broader efficacy by preventing extravascular hemolysis, potentially improving hematological responses.
• Deeper C5 inhibition is achievable, but its clinical significance requires further investigation.

Conclusions:

• New complement inhibitors targeting C5 and C3 are in clinical development for PNH.
• These agents promise enhanced patient convenience and potentially broader therapeutic benefits.
• The evolving landscape of complement inhibition is poised to significantly improve PNH management.